Search

Your search keyword '"Bowtell, David D. L."' showing total 295 results

Search Constraints

Start Over You searched for: Author "Bowtell, David D. L." Remove constraint Author: "Bowtell, David D. L."
295 results on '"Bowtell, David D. L."'

Search Results

1. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

2. Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

3. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

5. Interferon-ε is a tumour suppressor and restricts ovarian cancer

6. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

7. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

9. Homologous recombination proficient subtypes of highgrade serous ovarian cancer: treatment options for a poor prognosis group.

10. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer

12. Table S4 from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

13. Supplementary Data from Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype

14. Supplementary Data from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

15. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

16. The molecular origin and taxonomy of mucinous ovarian carcinoma

20. Synthetic lethality between CCNE1 amplification and loss of BRCA1

22. Whole–genome characterization of chemoresistant ovarian cancer

24. Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

25. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

26. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing

28. Inferring structural variant cancer cell fraction

29. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations

30. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition

31. Genomic footprints of activated telomere maintenance mechanisms in cancer

32. Additional file 1 of Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei

33. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

34. Pan-cancer analysis of whole genomes

36. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer

38. Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models

39. International network of cancer genome projects

40. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.

42. Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer

43. Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER

44. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype

45. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference

46. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.

47. Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei.

48. Genomic footprints of activated telomere maintenance mechanisms in cancer.

49. Patterns of somatic structural variation in human cancer genomes.

Catalog

Books, media, physical & digital resources